Effect of basic fibroblast growth factor on corneal epithelial healing after photorefractive keratectomy.
Alessandro Meduri, Pasquale Aragona, Pier L Grenga...
https://pubmed.ncbi.nlm.nih.gov/22230058/Actively Recruiting
Led by Henry M. Jackson Foundation for the Advancement of Military Medicine · Updated on 2026-09-03
88
Participants Needed
1
Research Sites
13 weeks
Total Duration
Researchers are evaluating the safety and effectiveness of Lacripep, an eyedrop medication, for repairing superficial corneal injuries after Photorefractive keratectomy PRK. This study focuses on improving healing of the cornea, the clear tissue covering the front of the eye, which can be damaged by trauma or surgery. Participants include active-duty military members or their dependents eligible for care at a military medical center. Participants will receive Lacripep in one eye and a placebo in the other eye simultaneously. The study measures how well Lacripep promotes corneal wound healing and maintains ocular surface health following PRK surgery. The treatment effects will be assessed over several months with evaluations at 4 and 7 days post-surgery, then at 1, 3, and 6 months. This phase 2 trial involves a single group receiving both treatments concurrently. During the study, participants will undergo regular assessments including epithelial thickness measurements to evaluate healing. Safety monitoring will occur from enrollment until the end of treatment at 6 months. Participants must be able to attend follow-up visits during this period. The main outcome measured is the effectiveness of Lacripep in corneal repair, along with monitoring for any side effects or safety concerns throughout the study duration.
CONDITIONS
Lacripep for Corneal Wound Healing Study
B
Benjamin G Kuhar, OD
R
Rose Sia
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Henry M. Jackson Foundation for the Advancement of Military Medicine
Lead Sponsor
TearSolutions, Inc.
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Lacripep (one eye, post-PRK) | Standard Care (artificial tears/lubricants) |
|---|---|---|
| What it is | A topical peptide-based eye drop (Lacripep) applied to one eye after PRK (the other eye receives placebo), being investigated for its effects on corneal epithelial wound healing. | Current standard post-PRK management usually involves frequent application of artificial tears or lubricating eye drops to support corneal epithelial healing and comfort. |
| Primary use | Investigational use to promote and evaluate corneal epithelial wound healing after refractive surgery. | Facilitate corneal epithelial healing, lubricate the ocular surface, and provide comfort after PRK. |
| How it is given or performed | Lacripep solution is applied as topical eye drops to one eye, while the opposite eye receives placebo drops, in addition to any standard post-operative care. | Artificial tears or lubricant drops are used as topical eye drops, generally given frequently throughout the day in the early post-PRK period. |
| Evidence status | Currently under investigation; established clinical outcome evidence in corneal wound healing after PRK is not yet published. | Widely supported in practice guidelines and literature as the established first-line approach for post-PRK wound care, though individual benefit may vary. |
| Important limitations | Efficacy and safety for wound healing after PRK are not yet established; study is ongoing. Only one eye receives Lacripep, the other receives placebo, so participants may experience different healing in each eye. | Artificial tears/lubricants provide symptomatic relief but do not actively accelerate epithelial regeneration; healing rates and comfort may vary among individuals. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 6 months
Participants receive Lacripep eyedrops in one eye and a placebo in the other eye after bilateral PRK surgery.
Follow-up visits at 4 and 7 days, then at 1, 3, and 6 months post-surgery
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Alessandro Meduri, Pasquale Aragona, Pier L Grenga...
https://pubmed.ncbi.nlm.nih.gov/22230058/Antonio Leccisotti
https://pubmed.ncbi.nlm.nih.gov/18362654/J S Heier, R W Enzenauer, S F Wintermeyer...
https://pubmed.ncbi.nlm.nih.gov/8512480/Trinka Vijmasi, Feeling Y T Chen, Suganthalakshmi Balasubbu...
https://pubmed.ncbi.nlm.nih.gov/25034600/Sandeep Samudre, Frank A Lattanzio, Victoria Lossen...
https://pubmed.ncbi.nlm.nih.gov/21087963/E John Gallagher, Polly E Bijur, Clarke Latimer...
https://pubmed.ncbi.nlm.nih.gov/12098173/Robert L McKown, Erin V Coleman Frazier, Kaneil K Zadrozny...
https://pubmed.ncbi.nlm.nih.gov/24942736/Joseph Tauber, Gordon W Laurie, Edward C Parsons...
https://pubmed.ncbi.nlm.nih.gov/35942530/Rajesh Fogla, Gaurav Luthra, Aishwarya Chhabra...
https://pubmed.ncbi.nlm.nih.gov/33229660/L J DeLoach, M S Higgins, A B Caplan...
https://pubmed.ncbi.nlm.nih.gov/9428860/Henry M. Jackson Foundation for the Advancement of Military Medicine
Lead Sponsor
TearSolutions, Inc.
Collaborating Sponsor